Close Menu

hospital-acquired infection

Bioinformatics firm Next Gen Diagnostics will integrate Fluidigm's Juno microfluidic sample prep system into its workflow for pathogen whole-genome sequencing.

The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.

The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents. 

Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.

An analysis of more than 900 C. difficile isolates uncovered four phylogenetic lineages, including three lineages in a clade showing recent positive selection on infection-related genes.

With whole-genome sequences and other analyses, researchers delved into drug resistance and more in 600 staphylococcus isolates from high-touch surfaces in East and West London.

The Branford, Connecticut-based startup plans to seek US Food and Drug Administration clearance for and launch its instrument and first assays in 2021.

The test is the fourth assay on the firm's Revogene system and it detects five common genetic causes of drug resistance.

Multi-drug resistant Enterococcus faecalis isolates from a Wisconsin hospital contained independent mutations falling at overlapping resistance-related loci.

Researchers in the US and Europe are implementing pathogen sequencing surveillance programs to track infectious diseases within hospitals.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.